Abcam, ab264819, Human ITGA2 (CD49b) knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
ITGA2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 14 bp deletion in exon 4. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 14 bp deletion in exon 4,
Antibiotic resistance:Puromycin 1µg/mL,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ITGA2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD49b also known as Integrin alpha-2 or ITGA2 is a transmembrane glycoprotein with a molecular weight of approximately 160 kDa. This protein localizes on the surface of various cells including platelets fibroblasts and some immune cells. It functions as part of the integrin family which are receptors that mediate the cell-extracellular matrix (ECM) interactions. CD49b binds to collagen and laminin in the ECM and contributes to cellular adhesion and signal transduction.
Biological function summary
The CD49b protein plays a critical role in cell migration thrombosis and wound healing. By forming a heterodimer with Integrin beta-1 it becomes a part of the collagen receptor complex Integrin alpha-2/beta-1 which facilitates various cellular interactions with the ECM. This functionality enables cells to sense their environment and respond to mechanical changes which is important for processes such as tissue repair and embryonic development.
Pathways
Several cellular mechanisms involve CD49b in maintaining physiological homeostasis. One significant pathway is the integrin signaling pathway where CD49b interacts with focal adhesion kinase (FAK) and other intracellular proteins to regulate cytoskeletal rearrangement and cell motility. Another pathway is platelet activation where CD49b collaborates with glycoprotein VI (GPVI) and other receptors to initiate platelet aggregation during hemostasis. These pathways highlight the importance of CD49b in various cellular functions related to cell mobility and stability.
Researchers have linked CD49b to conditions including thrombosis and fibrosis. In thrombosis abnormal platelet aggregation often involves CD49b and its interaction with fibrinogen and von Willebrand factor. In fibrosis CD49b's role in cell adhesion and matrix remodeling correlates with excessive ECM deposition and scar formation. Understanding CD49b's function offers insights into therapeutic strategies alongside related proteins such as Integrin beta-1 which may modulate disease progression.